-transparent.png){kind=logo}
The relative bioavailability of isosorbide-5-mononitrate from two different formulations (MONOCLAIR, ISMO) was investigated in a double-blind randomized cross-over study in 8 healthy human subjects. After single orale doses of 40 mg the plasma concentration and the urinary excretion of isosorbide-5-mononitrate were measured over 24 hours. The comparison of the results obtained over the whole experimental period showed a significantly higher plasma concentration with a higher renal excretion after MONOCLAIR, the latter changes being insignificant as compared with those after ISMO, the reference drug. Thus the two formulations are judged to be at least equivalent with regard to their drug bioavailability.
H Rameis, and
S Bacher, and
H G Eichler, and
H Horwatitsch
January 1981,
Biopharmaceutics & drug disposition,
H Rameis, and
S Bacher, and
H G Eichler, and
H Horwatitsch
January 1987,
Cardiology,
H Rameis, and
S Bacher, and
H G Eichler, and
H Horwatitsch
September 1989,
International journal of clinical pharmacology, therapy, and toxicology,
H Rameis, and
S Bacher, and
H G Eichler, and
H Horwatitsch
November 1987,
Cardiologia (Rome, Italy),
H Rameis, and
S Bacher, and
H G Eichler, and
H Horwatitsch
June 1992,
Journal of clinical pharmacology,
H Rameis, and
S Bacher, and
H G Eichler, and
H Horwatitsch
January 1981,
European journal of clinical pharmacology,
H Rameis, and
S Bacher, and
H G Eichler, and
H Horwatitsch
November 1985,
Deutsche medizinische Wochenschrift (1946),
H Rameis, and
S Bacher, and
H G Eichler, and
H Horwatitsch
March 1987,
International journal of clinical pharmacology, therapy, and toxicology,
H Rameis, and
S Bacher, and
H G Eichler, and
H Horwatitsch
August 1999,
Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego,
H Rameis, and
S Bacher, and
H G Eichler, and
H Horwatitsch
January 1982,
Arzneimittel-Forschung,
